Genprex (2DE1) Stock Price & Analysis

2DE1 Stock Chart & Stats

€3.96€0.00(0.00%)

At close: Oct 30 1:00 AM GMT+1

No data to display

Day’s Range: EUR 3.96 - EUR 3.96
52-Week Range: EUR 3.96 - EUR 3.96
Previous Close: EUR 3.96
Volume: N/A
Average Volume (3M): 0
Market Cap: EUR 1.64M
Enterprise Value: -EUR 17.26T
Total Cash (Recent Filing): EUR 15.15M
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: -0.30
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Genprex News

Genprex highlights TUSC2 gene therapy aging research

Genprex ( ($GNPX) ) has provided an update. On October 28, 2026, Genprex announced that research from its sponsored collaboration with Meharry Medical College will be featured at the Gerontological

5d ago8K GNPX

Genprex Highlights New TUSC2 Brain Aging Research

Genprex ( ($GNPX) ) has issued an update. On October 21, 2026, Genprex highlighted new peer-reviewed research in mice underscoring a key role for the TUSC2 tumor suppressor gene in

1w ago8K GNPX

Genprex highlights new peer-reviewed research on TUSC2 tumor suppressor gene

Genprex (GNPX) highlighted new peer-reviewed research in mice identifying an important role for the TUSC2 tumor suppressor gene in maintaining cellular processes associated with healthy brain aging and supporting broader

1w agoGNPX 2DE1

Genprex advances AAV diabetes gene therapy manufacturing

Genprex ( ($GNPX) ) just unveiled an announcement. On August 18, 2026, Genprex announced a development and manufacturing agreement with a leading U.S. CDMO to scale up manufacturing of its

2M ago8K GNPX

Genprex selects manufacturing organization for diabetes gene therapy

Genprex (GNPX) has entered into a development and manufacturing agreement with a U.S. based clinical and commercial Contract Development and Manufacturing Organization, or CDMO, to initiate the manufacturing scale-up of

2M agoGNPX 2DE1

Genprex Regains Nasdaq Compliance, Listing Status Secured

An update from Genprex ( ($GNPX) ) is now available. On July 29, 2026, a Nasdaq Hearings Panel granted Genprex an exception to continue its listing while it worked to

2M ago8K GNPX

Genprex, Roche Partner on NSCLC Biomarker Validation

Genprex ( ($GNPX) ) has issued an update. On August 3, 2026, Genprex announced a collaboration with Roche Diagnostics to validate biomarkers, notably TROP2 and PTEN, for selecting non-small cell

3M ago8K GNPX

Genprex announces collaboration with Roche Diagnostics

Genprex (GNPX) announced its collaboration with Roche Diagnostics (RHHBY) to validate biomarkers for patient selection in clinical trials for non-small cell lung cancer. Building on promising preclinical and clinical data,

3M agoCHRO GNPX

Genprex Granted Nasdaq Listing Exception Amid Compliance Push

Genprex ( ($GNPX) ) has shared an announcement. On July 29, 2026, a Nasdaq Hearings Panel granted Genprex an exception allowing its shares to remain listed on The Nasdaq Capital

3M ago8K GNPX

2DE1 FAQ

What was Genprex’s price range in the past 12 months?

Genprex lowest stock price was €3.96 and its highest was €3.96 in the past 12 months.

What is Genprex’s market cap?

Genprex’s market cap is €1.64M.

When is Genprex’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Genprex’s earnings last quarter?

Genprex released its earnings results on Aug 13, 2019. The company reported -€0.204 earnings per share for the quarter.

Is Genprex overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Genprex pay dividends?

Genprex does not currently pay dividends.

What is Genprex’s EPS estimate?

Genprex’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Genprex have?

Genprex has 819,709 shares outstanding.

What happened to Genprex’s price movement after its last earnings report?

Genprex reported an EPS of -€0.204 in its last earnings report. Following the earnings report the stock price went same ―.

Which hedge fund is a major shareholder of Genprex?

Currently, no hedge funds are holding shares in DE:2DE1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Genprex

Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer. In addition, Genprex is progressing GPX-002, another gene therapy at the preclinical stage, intended for the management of diabetes. The company was established in 2009 and operates from its corporate headquarters located in Austin, Texas.

Genprex (2DE1) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	4	5	5
Technical Analysis	0	1	1
Moving Averages	4	4	4

Technical Analysis >

Similar Stocks

Stocks similar to DE:2DE1
Company	Price & Change	Follow
KZIAKazia Therapeutics
BOLTBolt Biotherapeutics
INTSIntensity Therapeutics, Inc.

Compare DE:2DE1 Stocks >

Ownership Overview

10.43% Insiders
1.75% Mutual Funds
0.12% Other Institutional Investors
87.50% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft